Compare TNC & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNC | NVAX |
|---|---|---|
| Founded | 1870 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.6B |
| IPO Year | 1994 | 1996 |
| Metric | TNC | NVAX |
|---|---|---|
| Price | $64.67 | $9.44 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 9 |
| Target Price | ★ $91.00 | $11.33 |
| AVG Volume (30 Days) | 316.9K | ★ 4.4M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | 2.36 | ★ 2.58 |
| Revenue | ★ $1,137,600,000.00 | $1,123,479,000.00 |
| Revenue This Year | $5.44 | N/A |
| Revenue Next Year | $5.28 | N/A |
| P/E Ratio | $27.50 | ★ $3.77 |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $60.18 | $5.01 |
| 52 Week High | $85.91 | $11.85 |
| Indicator | TNC | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 41.17 | 46.76 |
| Support Level | $60.18 | $9.14 |
| Resistance Level | $84.24 | $10.42 |
| Average True Range (ATR) | 1.84 | 0.60 |
| MACD | 0.67 | -0.13 |
| Stochastic Oscillator | 85.50 | 16.52 |
Tennant Co is engaged in designing, manufacturing and marketing solutions that empower customers to achieve quality cleaning performance, reduce environmental impact and help create a cleaner, safer, healthier world. The Company is committed to creating and commercializing breakthrough, sustainable cleaning innovations to enhance its broad suite of products, including floor maintenance and cleaning equipment, detergent-free and other sustainable cleaning technologies, aftermarket parts and consumables, equipment maintenance and repair service, and asset management solutions. Its products are used in many types of environments, including retail establishments, distribution centers, factories and warehouses, public venues such as arenas and stadiums, office buildings, schools, and more.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.